Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 202


Molecular techniques for the personalised management of patients with chronic myeloid leukaemia.

Alikian M, Gale RP, Apperley JF, Foroni L.

Biomol Detect Quantif. 2017 Feb 14;11:4-20. doi: 10.1016/j.bdq.2017.01.001. eCollection 2017 Mar. Review.


Liquid Chromatography-Mass Spectrometry/Mass Spectrometry Analysis and Pharmacokinetic Assessment of Ponatinib in Sprague-Dawley Rats.

Wang P, Peng Y, Zhang X, Fei F, Wang S, Feng S, Huang J, Wang H, Aa J, Wang G.

Oncol Ther. 2016;4(1):117-128. doi: 10.1007/s40487-016-0022-2. Epub 2016 Jun 6.


Absorption, metabolism, and excretion of [14C]ponatinib after a single oral dose in humans.

Ye YE, Woodward CN, Narasimhan NI.

Cancer Chemother Pharmacol. 2017 Mar;79(3):507-518. doi: 10.1007/s00280-017-3240-x. Epub 2017 Feb 9.


Imatinib relaxes the pulmonary venous bed of guinea pigs.

Maihöfer NA, Suleiman S, Dreymüller D, Manley PW, Rossaint R, Uhlig S, Martin C, Rieg AD.

Respir Res. 2017 Feb 8;18(1):32. doi: 10.1186/s12931-017-0514-0.


Aurora A Kinase Inhibitor AKI603 Induces Cellular Senescence in Chronic Myeloid Leukemia Cells Harboring T315I Mutation.

Wang LX, Wang JD, Chen JJ, Long B, Liu LL, Tu XX, Luo Y, Hu Y, Lin DJ, Lu G, Long ZJ, Liu Q.

Sci Rep. 2016 Nov 8;6:35533. doi: 10.1038/srep35533.


Transposon-mediated generation of BCR-ABL1-expressing transgenic cell lines for unbiased sensitivity testing of tyrosine kinase inhibitors.

Byrgazov K, Lucini CB, Berkowitsch B, Koenig M, Haas OA, Hoermann G, Valent P, Lion T.

Oncotarget. 2016 Nov 22;7(47):78083-78094. doi: 10.18632/oncotarget.12943.


Validated LC-MS/MS Method for the Quantification of Ponatinib in Plasma: Application to Metabolic Stability.

Kadi AA, Darwish HW, Attwa MW, Amer SM.

PLoS One. 2016 Oct 20;11(10):e0164967. doi: 10.1371/journal.pone.0164967. eCollection 2016.


Novel multiple tyrosine kinase inhibitor ponatinib inhibits bFGF-activated signaling in neuroblastoma cells and suppresses neuroblastoma growth in vivo.

Li H, Wang Y, Chen Z, Lu J, Pan J, Yu Y, Zhao Y, Zhang H, Hu T, Liu Q, Yang J.

Oncotarget. 2017 Jan 24;8(4):5874-5884. doi: 10.18632/oncotarget.11580.


The human Smoothened inhibitor PF-04449913 induces exit from quiescence and loss of multipotent Drosophila hematopoietic progenitor cells.

Giordani G, Barraco M, Giangrande A, Martinelli G, Guadagnuolo V, Simonetti G, Perini G, Bernardoni R.

Oncotarget. 2016 Aug 23;7(34):55313-55327. doi: 10.18632/oncotarget.10879.


Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A propensity score analysis.

Sasaki K, Jabbour EJ, Ravandi F, Short NJ, Thomas DA, Garcia-Manero G, Daver NG, Kadia TM, Konopleva MY, Jain N, Issa GC, Jeanis V, Moore HG, Garris RS, Pemmaraju N, Cortes JE, O'Brien SM, Kantarjian HM.

Cancer. 2016 Dec 1;122(23):3650-3656. doi: 10.1002/cncr.30231. Epub 2016 Aug 1.


Sensitivity of imatinib-resistant T315I BCR-ABL CML to a synergistic combination of ponatinib and forskolin treatment.

Oaxaca DM, Yang-Reid SA, Ross JA, Rodriguez G, Staniswalis JG, Kirken RA.

Tumour Biol. 2016 Sep;37(9):12643-12654. Epub 2016 Jul 21.


SCLLTargeting FGFR1 to suppress leukemogenesis in syndromic and de novo AML in murine models.

Wu Q, Bhole A, Qin H, Karp J, Malek S, Cowell JK, Ren M.

Oncotarget. 2016 Aug 2;7(31):49733-49742. doi: 10.18632/oncotarget.10438.


A place for precision medicine in bladder cancer: targeting the FGFRs.

di Martino E, Tomlinson DC, Williams SV, Knowles MA.

Future Oncol. 2016 Oct;12(19):2243-63. doi: 10.2217/fon-2016-0042. Epub 2016 Jul 6. Review.


Discovery and characterization of a novel potent type II native and mutant BCR-ABL inhibitor (CHMFL-074) for Chronic Myeloid Leukemia (CML).

Liu F, Wang B, Wang Q, Qi Z, Chen C, Kong LL, Chen JY, Liu X, Wang A, Hu C, Wang W, Wang H, Wu F, Ruan Y, Qi S, Liu J, Zou F, Hu Z, Wang W, Wang L, Zhang S, Yun CH, Zhai Z, Liu J, Liu Q.

Oncotarget. 2016 Jul 19;7(29):45562-45574. doi: 10.18632/oncotarget.10037.


FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review).

Katoh M.

Int J Mol Med. 2016 Jul;38(1):3-15. doi: 10.3892/ijmm.2016.2620. Epub 2016 May 31. Review.


Structure-Based Design of Tetrahydroisoquinoline-7-carboxamides as Selective Discoidin Domain Receptor 1 (DDR1) Inhibitors.

Wang Z, Bian H, Bartual SG, Du W, Luo J, Zhao H, Zhang S, Mo C, Zhou Y, Xu Y, Tu Z, Ren X, Lu X, Brekken RA, Yao L, Bullock AN, Su J, Ding K.

J Med Chem. 2016 Jun 23;59(12):5911-6. doi: 10.1021/acs.jmedchem.6b00140. Epub 2016 Jun 3.


Antitumor effect of FGFR inhibitors on a novel cholangiocarcinoma patient derived xenograft mouse model endogenously expressing an FGFR2-CCDC6 fusion protein.

Wang Y, Ding X, Wang S, Moser CD, Shaleh HM, Mohamed EA, Chaiteerakij R, Allotey LK, Chen G, Miyabe K, McNulty MS, Ndzengue A, Barr Fritcher EG, Knudson RA, Greipp PT, Clark KJ, Torbenson MS, Kipp BR, Zhou J, Barrett MT, Gustafson MP, Alberts SR, Borad MJ, Roberts LR.

Cancer Lett. 2016 Sep 28;380(1):163-73. doi: 10.1016/j.canlet.2016.05.017. Epub 2016 May 20.


Combination of panobinostat with ponatinib synergistically overcomes imatinib-resistant CML cells.

Matsuda Y, Yamauchi T, Hosono N, Uzui K, Negoro E, Morinaga K, Nishi R, Yoshida A, Kimura S, Maekawa T, Ueda T.

Cancer Sci. 2016 Jul;107(7):1029-38. doi: 10.1111/cas.12965. Epub 2016 Jun 21.


Chronic myeloid leukemia: reminiscences and dreams.

Mughal TI, Radich JP, Deininger MW, Apperley JF, Hughes TP, Harrison CJ, Gambacorti-Passerini C, Saglio G, Cortes J, Daley GQ.

Haematologica. 2016 May;101(5):541-58. doi: 10.3324/haematol.2015.139337. Review.


Mechanisms of Cardiotoxicity of Cancer Chemotherapeutic Agents: Cardiomyopathy and Beyond.

Moudgil R, Yeh ET.

Can J Cardiol. 2016 Jul;32(7):863-870.e5. doi: 10.1016/j.cjca.2016.01.027. Epub 2016 Feb 2. Review.


Supplemental Content

Support Center